Advertisement


Hossein Borghaei, DO, on Bispecific T-Cell–Engager Immune Therapy for Small Cell Lung Cancer

IASLC 2020 World Conference on Lung Cancer in Singapore

Advertisement

Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase I results from a study of AMG 757, an experimental bispecific T-cell–engager (BiTE) immune therapy aimed at the DLL3 molecular target in patients with small cell lung cancer. At this early stage, results show clinical efficacy and safety, with 37% of 51 evaluable patients exhibiting disease control (Abstract OA11.03).



Related Videos

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment

Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more benefit in terms of efficacy than pembrolizumab plus placebo in first-line therapy for patients with metastatic high PD-L1–expressing non–small cell lung cancer (Abstract PS01.09).

Solid Tumors
Immunotherapy

Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success for developing this treatment, and some study results to date (Abstract PL03.05).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab, Platinum Chemotherapy, and Radiotherapy in Advanced Disease

Martin Reck, MD, PhD, of the LungenClinic, discusses the results from KEYNOTE-799, which explored a new strategy to increase the intensity of treatment in patients with unresectable, locally advanced, stage III non–small cell lung cancer (Abstract OA02.03).

Lung Cancer
Immunotherapy

Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).

Lung Cancer
Immunotherapy

Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease

Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of mesothelioma is on the rise; in the United Kingdom alone, it has gone up nearly 500% since the 1970s (Abstract PS01.11).

Advertisement

Advertisement



Advertisement